Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition

Completion Of $425m Deal Comes Shortly After FTC Approved The Transaction

Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.

Complete Word Jigsaw Pieces
Hikma has now completed its deal to acquire Custopharm • Source: Cagkan Sayin / Alamy Stock Photo

Hikma has now completed its acquisition of US sterile injectables specialist Custopharm from Water Street Healthcare Partners, in a deal that promises to further expand its US injectables business.

The transaction – which is worth up to $425m, comprising a $375m upfront purchase price and a further $50m in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

 
• By 

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.

Intas Expands Its Plasma Business With A European Acquisition

 

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By 

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

More from Business

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By 

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Fresenius Kabi Pharma Bounces Back In Q2 With Strong US and Europe Volumes

 
• By 

Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.

Intas Expands Its Plasma Business With A European Acquisition

 

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.